Literature DB >> 26139003

Comparison of estimated human dose of (68)Ga-MAA with (99m)Tc-MAA based on rat data.

Saeed Shanehsazzadeh1, Afsaneh Lahooti2, Hassan Yousefnia3, Parham Geramifar4, Amir Reza Jalilian3.   

Abstract

OBJECTIVE: (99m)Tc macroaggregated albumin ((99m)Tc-MAA) that had been used as a perfusion agent has been evaluated. In this study, we tried to estimate human absorbed dose of ⁶⁸Ga-MAA via commercially available kit from Pars-Isotopes, based on biodistribution data in wild-type rats, and compare our estimation with the available absorbed dose data from (99m)Tc-MAA.
METHODS: For biodistribution of ⁶⁸Ga-MAA, three rats were sacrificed at each selected times after injection (15, 30, 45, 60, and 120 min) and the percentage of injected dose per gram of each organ was measured by direct counting from rats data from 11 harvested organs. The medical internal radiation dose formulation was applied to extrapolate from rats to human and to project the absorbed radiation dose for various organs in humans.
RESULTS: The biodistribution data for ⁶⁸Ga-MAA showed that the most of the activity was taken up by the lung (more than 97 %) in no time. Our dose prediction shows that a 185-MBq injection of ⁶⁸Ga-MAA into humans might result in an estimated absorbed dose of 4.31 mGy in the whole body. The highest absorbed doses are observed in the adrenals, spleen, pancreas, and red marrow with 0.36, 0.34, 0.26, and 0.19 mGy, respectively.
CONCLUSION: Since the (99m)Tc-MAA remains longer than ⁶⁸Ga-MAA in the lung and ⁶⁸Ga-MAA has good image qualities and results in lower amounts of dose delivery to the critical organs such as gonads, red marrow, and adrenals, the use of ⁶⁸Ga-MAA is recommended.

Entities:  

Keywords:  Biodistribution; Effective absorbed dose; Gallium 68; Macroaggregated albumin (MAA)

Mesh:

Substances:

Year:  2015        PMID: 26139003     DOI: 10.1007/s12149-015-0997-z

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  3 in total

Review 1.  Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Authors:  Nicolas Lepareur
Journal:  Front Med (Lausanne)       Date:  2022-02-10

2.  Human Absorbed Dose Estimation of 111In-DOTA-PR81 as a Novel High Potential Agent for Breast Cancer Imaging.

Authors:  Hassan Yousefnia; Samaneh Zolghadri; Behrouz Alirezapour
Journal:  J Med Phys       Date:  2022-08-05

3.  A Supramolecular Approach for Liver Radioembolization.

Authors:  Silvia J Spa; Mick M Welling; Matthias N van Oosterom; Daphne D D Rietbergen; Mark C Burgmans; Willem Verboom; Jurriaan Huskens; Tessa Buckle; Fijs W B van Leeuwen
Journal:  Theranostics       Date:  2018-03-23       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.